Results Wire: US FDA Advisory Committee Unanimously Supports Novartis’ Cosentyx (Secukinumab) for Psoriasis and Gives Input on Optimal Dosing - OCT 20, 2014 (DODAC)

On Monday, October 20, 2014 the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) unanimously supported, by a vote of 7-Yes to 0-No, the approval of Novartis’ Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

See the SAC Tracker Report